Bacteriophage therapy

01Overview and value chain#

Markers EC: REACH | OECD: bio-pharma | Regulator: FDA (USA), NMPA (China), EMA (EU)

Bacteriophages are viruses that infect and lyse bacteria with strain-level specificity, offering a mechanism of action that does not select for the broad-spectrum resistance driving the antimicrobial-resistance (AMR) crisis. The field’s central engineering problem is also its central business problem: a single phage typically covers only a narrow slice of a pathogen’s strain diversity, so a therapeutic product is usually a cocktail of several phages (or a single phage engineered for broader host range), and that cocktail has to be periodically refreshed as target strains evolve — a manufacturing and regulatory model closer to a vaccine than a conventional small-molecule antibiotic. 2025 supplied both directions of evidence at once: Armata Pharmaceuticals’ AP-SA02 read out positive Phase 2a data in S. aureus bacteremia and is advancing to Phase 3, while France’s Phaxiam Therapeutics — formed from the 2023 merger of phage pioneer Pherecydes with Erytech — was placed into judicial liquidation in June 2025 after its lead PhagoBurn-descended candidate failed to show sufficient efficacy. The science works in the right patient; building a regulatable, financeable product around it is still the open problem.

The key directions are:

1. Fixed phage cocktails: A pre-manufactured mixture of several lytic phages targeting a pathogen’s most common strains, dosed like a conventional biologic.
2. CRISPR-enhanced phage: Phage engineered to carry a CRISPR-Cas payload that kills bacteria carrying a resistance or virulence gene while sparing susceptible strains, widening effective host range without a broader phage mixture.
3. Personalized/adaptive phage therapy: Phage selected or evolved against a specific patient’s isolated pathogen strain, typically under expanded-access or compassionate-use pathways rather than as an off-the-shelf product.
4. Topical and surface applications: Phage formulated for wound, burn or device-surface application, where local delivery sidesteps some of the systemic PK/PD questions still open for IV phage.

Sectoral value chain#

[Pathogen strain surveillance] ──> [Phage isolation/engineering] ──> [GMP phage banking & titer QC] ──> [Cocktail formulation]
                                  │
                          (Host-range & resistance testing)
                                  │
                                  ▼
[Clinical administration] <─── [Fill-finish & cold chain] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Host-range testing: Systematic plaque assays against strain panels to define which pathogen isolates a phage or cocktail actually covers before it ships.
• CRISPR-Cas payload delivery: Using phage as a delivery vehicle for a CRISPR nuclease that cuts a resistance or virulence gene, converting phage from a lytic agent alone into a gene-targeted one.
• Phage-antibiotic synergy testing: Screening phage-antibiotic combinations for synergistic killing, since most current trials dose phage as an adjunct to antibiotics rather than a replacement.

02US#

The United States has the most clinically advanced phage-therapy pipeline, anchored by two companies now in randomized controlled trials rather than compassionate-use case series.

Phase 3-track programs, CRISPR-enhanced phage, cystic fibrosis focus#

• Armata Pharmaceuticals: AP-SA02, an IV phage cocktail dosed alongside standard antibiotics for complicated S. aureus bacteremia, read out positive Phase 2a data in May 2025, received FDA Qualified Infectious Disease Product designation, and is set to begin Phase 3 in the second half of 2026 — the furthest along any Western phage candidate has reached.
• Locus Biosciences: LBP-EC01 pairs a lytic phage with a CRISPR-Cas3 payload targeting E. coli, and completed the first randomized, placebo-controlled trial of a recombinant phage therapy, reducing susceptible-bacteria levels in patients with E. coli urinary tract infection.
• Felix Biotechnology: backed by the Cystic Fibrosis Foundation, is running the Yale-based CYPHY Phase 1/2 trial of YPT-01 against chronic P. aeruginosa lung infection in CF patients — a chronic, biofilm-forming indication where conventional antibiotics manage but rarely clear infection.

03CN#

China’s phage clinical infrastructure is younger and smaller than the US/EU pipeline, built around a single dedicated research institute rather than a venture-funded company cohort — a genuine gap, not a coverage oversight.

Institute-led clinical qualification, no confirmed commercial-stage producer#

• Shanghai Institute of Phage: established in 2017, it was the first institution in China to obtain qualification for clinical bacteriophage treatment and launched the country’s first ethically approved phage-therapy clinical trial in 2018, working case-by-case with hospitals on multidrug-resistant infections rather than running a Western-style sponsor-led trial.
• Academic engineering base: Chinese Academy of Sciences groups are active in engineered-phage research targeting drug-resistant pathogens, but as of this review none has spun out a company with a product in company-sponsored clinical trials comparable to Armata or Locus.
• No China-headquartered commercial phage-therapeutics company with a product in company-sponsored clinical trials was confirmed — the region’s current strength is institute-led compassionate-use treatment of individual patients, not a scalable commercial pipeline.

04EU#

Europe pioneered modern phage-therapy clinical research through the EU-funded PhagoBurn trial, but its most advanced commercial vehicle failed financially in 2025 — a genuine cautionary data point for anyone evaluating this sector, not a gap in the research.

PhagoBurn legacy, PHAXIAM’s 2025 liquidation, individualized-therapy pathways#

• PHAXIAM Therapeutics (formerly Pherecydes Pharma): formed in 2023 from Pherecydes’ merger with Erytech, PHAXIAM aimed to build a 35-45-phage GMP bank covering the most critical resistant pathogens by end-2026, with commercial IV and orthopedic-infection programs. The Lyon Commercial Court placed the company into judicial liquidation on 11 June 2025 after its lead candidate, descended from the earlier PhagoBurn P. aeruginosa burn-wound trial, failed to demonstrate sufficient efficacy — a direct illustration of how the field’s cocktail/coverage economics can sink even a well-funded, clinically active program.
• Individualized Phage Therapy pathways: Several EU hospital centers, including those that ran PhagoBurn, continue to treat individual patients under magistral/compassionate-use frameworks even without a company standing behind a registered product — the clinical practice has outlasted its most visible commercial vehicle.
• Regulatory framework: The EMA has no phage-specific approval pathway; sponsors route through existing biologic/ATMP frameworks not designed for a product whose active ingredient composition may need periodic updating as target strains evolve, a structural mismatch the field has not yet resolved.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack is dominated by the strain-coverage problem — proving a phage or cocktail actually kills the pathogen in front of a clinician, and keeping that coverage current as bacterial populations evolve.

1. CRISPR-Cas Payload Engineering:
   • Phage engineered to deliver a CRISPR nuclease that cuts a chromosomal resistance or virulence gene, killing target cells selectively while leaving susceptible commensal bacteria unaffected — Locus Biosciences’ core platform.
2. Rapid Host-Range Screening:
   • High-throughput plaque assays against curated clinical strain panels to characterize which isolates a candidate phage covers before it enters a cocktail, and to detect coverage drift over time.
3. Phage-Antibiotic Synergy Testing:
   • Checkerboard and time-kill assays screening phage-antibiotic combinations, since most current trial designs dose phage as an adjunct rather than monotherapy — the combination, not the phage alone, is usually what is being tested for efficacy.

07Value chains and production pipelines#

Industrial pipeline of GMP phage cocktail manufacturing (Clinical Grade)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Phage isolation from   │ ───> │ 2. Host-range & lytic      │
│    environmental/clinical │      │    activity screening      │
│    samples                 │      │                            │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. GMP amplification on   │ <─── │ 3. Master/working phage    │
│    production host        │      │    bank characterization  │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Purification & endotoxin│ ───> │ 6. Cocktail formulation &  │
│    removal                 │      │    fill-finish             │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Phage isolation from environmental/clinical samples

Wastewater, sewage or clinical isolate collections are screened for lytic phage active against the target pathogen, typically by mixing sample filtrate with a bacterial lawn and looking for clearance zones (plaques).

Stage 2: Host-range and lytic activity screening

Candidate phages are tested against a panel of clinical strain isolates to determine breadth of coverage and confirm strictly lytic (not lysogenic/temperate) behavior, since a temperate phage can integrate into the bacterial genome instead of killing it.

Stage 3: Master/working phage bank characterization

The selected phage is sequenced, characterized for genome content (screening out toxin or resistance genes it might carry), and banked as a master stock with defined titer for reproducible GMP production.

Stage 4: GMP amplification on production host

The phage is propagated on a qualified, non-pathogenic bacterial production host in bioreactors, generating high-titer lysate for downstream purification.

Stage 5: Purification and endotoxin removal

Chromatography and filtration steps separate phage particles from host-cell debris and endotoxin, which is a particular concern for phage grown on gram-negative production hosts and dosed intravenously.

Stage 6: Cocktail formulation and fill-finish

Multiple purified phages are combined to the target coverage panel, titer-adjusted, and aseptically filled, with cold-chain distribution required to preserve viable titer through to clinical administration.